ArticleBioinformatics (Oxford, England)2023
DataDTA: a multi-feature and dual-interaction aggregation framework for drug-target binding affinity prediction.
Article in Bioinformatics (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Protein Sequence Analysis landscape: A Systematic Review of Task Types, Databases, Datasets, Word Embeddings Methods, and Language Models.Database : the journal of biological databases and curation · 2025Pooled it
- [Prediction and verification of therapeutic drugs for triple-negative breast cancer using a knowledge graph-based drug repurposing model].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Structure-agnostic protein-ligand binding affinity prediction via hierarchical representation alignment.Bioinformatics (Oxford, England) · 2026Article
- Deep Contrastive Learning for High-Throughput Prediction of Drug Resistance Mutations from Sequences.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Computational approaches to druggable site identification: Current status and future perspective.Acta pharmaceutica Sinica. B · 2026Review
- In silico methods for drug-target interaction prediction.Cell reports methods · 2025Review
- DCMF-PPI: a protein-protein interaction predictor based on dynamic condition and multi-feature fusion.BMC bioinformatics · 2025Article
- Joint fusion of sequences and structures of drugs and targets for identifying targets based on intra and inter cross-attention mechanisms.BMC biology · 2025Article
- SP-DTI: subpocket-informed transformer for drug-target interaction prediction.Bioinformatics (Oxford, England) · 2025Article
- Dual modality feature fused neural network integrating binding site information for drug target affinity prediction.NPJ digital medicine · 2025Article
- Deep Drug-Target Binding Affinity Prediction Base on Multiple Feature Extraction and Fusion.ACS omega · 2025Article
- Improving drug-target affinity prediction by adaptive self-supervised learning.PeerJ. Computer science · 2025Article
- DeepTGIN: a novel hybrid multimodal approach using transformers and graph isomorphism networks for protein-ligand binding affinity prediction.Journal of cheminformatics · 2024Article
- Incorporating Water Molecules into Highly Accurate Binding Affinity Prediction for Proteins and Ligands.International journal of molecular sciences · 2024Article
- TEFDTA: a transformer encoder and fingerprint representation combined prediction method for bonded and non-bonded drug-target affinities.Bioinformatics (Oxford, England) · 2024Article
- A comprehensive review of the recent advances on predicting drug-target affinity based on deep learning.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
motivationAccurate prediction of drug-target binding affinity (DTA) is crucial for drug discovery. The increase in the publication of large-scale DTA datasets enables the development of various computational methods for DTA prediction. Numerous deep learning-based methods have been proposed to predict affinities, some of which only utilize original sequence information or complex structures, but the effective combination of various information and protein-binding pockets have not been fully mined. Therefore, a new method that integrates available key information is urgently needed to predict DTA and accelerate the drug discovery process.
resultsIn this study, we propose a novel deep learning-based predictor termed DataDTA to estimate the affinities of drug-target pairs. DataDTA utilizes descriptors of predicted pockets and sequences of proteins, as well as low-dimensional molecular features and SMILES strings of compounds as inputs. Specifically, the pockets were predicted from the three-dimensional structure of proteins and their descriptors were extracted as the partial input features for DTA prediction. The molecular representation of compounds based on algebraic graph features was collected to supplement the input information of targets. Furthermore, to ensure effective learning of multiscale interaction features, a dual-interaction aggregation neural network strategy was developed. DataDTA was compared with state-of-the-art methods on different datasets, and the results showed that DataDTA is a reliable prediction tool for affinities estimation. Specifically, the concordance index (CI) of DataDTA is 0.806 and the Pearson correlation coefficient (R) value is 0.814 on the test dataset, which is higher than other methods. AVAILABILITY AND IMPLEMENTATION: The codes and datasets of DataDTA are available at https://github.com/YanZhu06/DataDTA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.